Dacarbazine Resistance in Melanoma Is Driven by Cell Cycle Dysregulation Stemming from Altered Cyclin D1, GSK-3β, and p21 Expression
Anticancer Research · 2026-07 · 46 (7) · 3797-3804
DOI: 10.21873/anticanres.18241 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, online erschienen am 29.06.2026. Verfasst von Chinami Ikushima und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology I, School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women's University, Nishinomiya, Japan. Hauptthemen laut MEDLINE: Dacarbazine, Drug Resistance, Neoplasm, Cyclin D1, Cyclin-Dependent Kinase Inhibitor p21.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology I, School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women's University, Nishinomiya, Japan.
- Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
- Department of Pharmacology I, School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women's University, Nishinomiya, Japan; norikoy@mukogawa-u.ac.jp.
Zitieren
APA
Ikushima, C., Nakamura, K., Furuta, K., Iwata, E., & Yoshikawa, N. (2026). Dacarbazine Resistance in Melanoma Is Driven by Cell Cycle Dysregulation Stemming from Altered Cyclin D1, GSK-3β, and p21 Expression. Anticancer Research, 46(7), 3797-3804. https://doi.org/10.21873/anticanres.18241
Vancouver
Ikushima C, Nakamura K, Furuta K, Iwata E, Yoshikawa N. Dacarbazine Resistance in Melanoma Is Driven by Cell Cycle Dysregulation Stemming from Altered Cyclin D1, GSK-3β, and p21 Expression. Anticancer Research. 2026;46(7):3797-3804. doi:10.21873/anticanres.18241
BibTeX
@article{Ikushima2026,
author = {Ikushima, Chinami and Nakamura, Kazuki and Furuta, Kazuyuki and Iwata, Eriko and Yoshikawa, Noriko},
title = {Dacarbazine Resistance in Melanoma Is Driven by Cell Cycle Dysregulation Stemming from Altered Cyclin D1, GSK-3β, and p21 Expression},
journal = {Anticancer Research},
year = {2026},
volume = {46},
number = {7},
pages = {3797--3804},
doi = {10.21873/anticanres.18241}
}
EUVIMED